Sign in
Taking peopleNo phase

First test of the GEMINUS heart valve system in severe aortic stenosis

Tests the GEMINUS replacement heart valve in adults with severe, symptomatic aortic stenosis.

Key facts

Who runs it
Valve Medical
Where
Israel2 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
FIH Study of the GEMINUS TAVI System in Patients With Severe Symptomatic Aortic Stenosis
Status
Recruiting
People taking part
30 people, planned
Started
21 May 2023
Expected to end
Apr 2030
Type of study
Interventional
Treatments tested
  • GEMINUS Transcatheter Aortic Valve Implantation system
Record updated
21 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with severe aortic stenosis (a narrowed heart valve) that causes symptoms. They will receive the new GEMINUS valve through a catheter.

Age
18 years and older (record lists up to 120 Years).
Sex
All sexes can join.
Disease stage
Severe aortic stenosis by ACC/AHA 2020 guidelines, e.g. AVA ≤ 1.0 cm2 (or AVA index ≤ 0.6cm2/m2) and PV ≥ 4 m/sec or mean gradient ≥ 40 mmHg. Symptoms at NYHA Class II or higher. At least intermediate surgical risk, or age ≥75 years. Aortic annulus ≥22 mm and < 29 mm. Leg and pelvic arteries wider than 4mm. The heart team judges a high risk of bleeding or vessel problems at the access site.
Earlier treatment
No invasive heart treatment (except BAV) within 30 days before the procedure. No artificial heart valve in any position.

Main reasons for not taking part

  • Cannot have emergency open-heart surgery as a backup.
  • Heart valve infection now or within 6 months, or active body-wide infection.
  • Heart attack within 1 month, or stroke or TIA within 6 months.
  • Valve with one, two or four leaflets, or valve without calcium.
  • Kidney function eGFR<30 mL/min or on chronic dialysis.

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Patient understands the implications of participating in the study and provides informed consent
  • Patient is willing to comply with specified follow-up evaluation
  • Severe aortic stenosis as per ACC/AHA 2020 guidelines (e.g. AVA ≤ 1.0 cm2 (or AVA index ≤ 0.6cm2/m2)* AND PV ≥ 4 m/sec or mean gradient ≥ 40 mmHg)** as determined by TTE/CT-TAVI; *May be larger with mixed AS/AR; **For low flow low gradient AS or paradoxical low flow severe AS must meet ACC/AHA guidelines (table 13 stages of AS in the guideline)
  • Cardiac Symptoms: ≥ NYHA Class II
  • Patient ≥ intermediate surgical risk as assessed by the heart team or ≥75 years old
  • Aortic annulus diameter ≥22 mm and < 29 mm, assessed by CT TAVI
  • Anatomically suitable for implantation of the GEMINUS device
  • Peripheral vessels (common femoral and iliac arteries) of acceptable size (minimal diameter > 4mm), tortuosity, and calcification to accommodate the 12Fr catheter system
  • Patients assessed by the heart team to be at high risk for access site related bleeding/vascular complications due to the caliber/ calcification/ atherosclerosis of the iliofemoral vessels

Who cannot take part

  • Patient not suitable for surgical bailout
  • Active peptic ulcer or upper GI bleeding within the prior 3 months
  • Currently participating in an investigational drug or another device study that has not reached its primary endpoint
  • Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation ≥3+)
  • Active systemic infections
  • Any therapeutic invasive cardiac procedure (except BAV) performed within 30 days of the index procedure
  • Prosthetic heart valve in any position
  • Untreated clinically significant coronary artery disease requiring revascularization
  • Known hypersensitivity or contraindication to heparin, inability to tolerate antiplatelet therapy or sensitivity to contrast media (which cannot be adequately premedicated)
  • Severe aortic disease, including abdominal aortic or thoracic aneurysm (lumen diameter > 5cm), marked tortuosity, or severe aortic arch atheroma
  • Life expectancy < 12 months due to non-cardiac co-morbid conditions
  • Blood dyscrasias as defined: leukopenia (WBC<3000/mm3), acute anemia (Hb <8mg%), thrombocytopenia (platelet count <50,000 cells/mm3), history of bleeding diathesis or coagulopathy
  • Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) <20%
  • Renal insufficiency (eGFR<30 mL/min) and/or end stage renal disease requiring chronic dialysis
  • Congenital uni/bi/quadricuspid valve, or noncalcified aortic valve
  • Active or recent (within 6 months) endocarditis
  • Recent MI (≤ 1 month)
  • Severe (> 3+) mitral, tricuspid or pulmonic regurgitation
  • Hemodynamic instability requiring inotropic support or mechanical support devices
  • Hypertrophic cardiomyopathy with or without obstruction (HCM)
  • Echocardiographic evidence of intracardiac mass, thrombus or vegetation
  • Recent (<6 months) cerebrovascular accident (CVA) or transient ischemic attack (TIA)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 120 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main objective of this study is to evaluate the feasibility and safety of the GEMINUS system in patients with severe symptomatic aortic stenosis.

Read full original descriptionShow less

This is a prospective, open label, multicentre, single arm, first in human clinical study.

Clinical follow up for all patients will be performed at 30 days, 6 months, 1, 2, 3, 4 and 5 years post-implantation

The group in the trial

  • GEMINUS Transcatheter Aortic Valve Implantation systemTreatment being tested

    Clinical follow up for all patients will be performed at 30 days, 6 months, 1, 2, 3, 4 and 5 years post-implantation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
First in Human Study of the GEMINUS Transcatheter Aortic Valve Implantation System in Patients With Severe Symptomatic Aortic Stenosis
Plain-language title
First test of the GEMINUS heart valve system in severe aortic stenosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT05909748, who can take part
Record updated
21 August 2026